ObvioHealth Discusses the Rise of Real-World Data Within Clinical Trials

ObvioHealth brings attention to the current rise of real-world data and real-world evidence usage within clinical trials

Real-world data (RWD) within clinical trials is certainly a hot topic at the moment with doctors, biotech, and pharmaceutical companies alike, who all point to the tremendous possibilities and potential that come from leveraging this type of data for the improvement of health outcomes. ObvioHealth, one of the leading players in the clinical trial industry, decided to discuss what this kind of data means for trials and their participants.

They mention that RWD is used in a whopping 75% of new drug applications and Biologic License Applications since 2020. But as with any new technology or innovation, there is still a gap between RWD analysis and the reality of the practices currently being employed today. Obvio notes that there are currently significant challenges when it comes to collecting and analyzing mass amounts of disparate data in a secure and private way.

Real-world data relates to patient health status and/or health care delivery, which is routinely collected from a variety of sources, including electronic health records, claims and billing activities, product and disease registries, and also patient-generated data collected both at home and from health-monitoring devices.

Many people don’t understand the applications of real world data, and Obvio provides clarity on that topic by first mentioning that historically, the US Food and Drug Administration (FDA) used real-world data (RWD) and real-world evidence (RWE) to track post-market safety and adverse occurrences and make regulatory judgments. Both words traditionally referred to patient-level data collected outside of a traditional clinical research context.

Advances in technology, data science, and healthcare policies on the other hand, have considerably boosted the amount, sources, and usage of RWD beyond those already mentioned. RWD and RWE are increasingly being used by product developers in clinical trials to assist clinical trial designs as well as to monitor results.

And while there are currently barriers to the adoption, the future of RWD is bright and rife with the use of AI. RWD’s power is related to the amount and quality of the data collection under consideration. Given the limitations of data standards and data set interoperability, AI (artificial intelligence), NPL (natural language processing), and RPA (Robotic Process Automation) technologies will be increasingly used to aid in these efforts to uncover important insights.

To find out more about ObvioHealth and how they are working towards a change in the clinical trial industry, please see the following URL: https://www.obviohealth.com/

Release ID: 89057283